Publications scientifiques Bordet

Publications scientifiques Bordet

  • Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium.

  • Auteurs Franzoi MA, Ferreira AR, Lemaire A, Rodriguez J, Grosjean J, Ribeiro JM, Polastro L, Grellety T, Artignan X, Le Du K, Pagliuca M, Nouhaud É, Autheman M, André F, Basch E, Metzger O, Ferté C, Di Palma M, Scotté F, Vaz-Luis I
  • Auteurs (entité) POLASTRO LAURA
  • Revue Lancet Reg Health Eur
  • Date de publication 2024-09
Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium.
  • Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients.

  • Auteurs Assaf I, Bregni G, Anthoine G, Aparicio T, Artru P, Abdelghani MB, Buyse M, Chibaudel B, Coart E, Diaz M, Evrard C, Geboes K, Ghiringhelli F, Puleo F, Raimbourg J, Vandamme T, Van den Eynde M, Hendlisz A, Sclafani F
  • Auteurs (entité) BREGNI GIACOMO
  • Revue Clin Colorectal Cancer
  • Date de publication 2024-09
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients.
  • Coverage with evidence development program on stereotactic body radiotherapy in Belgium (2013-2019): a nationwide registry-based prospective study.

  • Auteurs Lievens Y, Janssens S, Lambrecht M, Engels H, Geets X, Jansen N, Moretti L, Remouchamps V, Roosens S, Stellamans K, Verellen D, Weltens C, Weytjens R, Van Damme N
  • Auteurs (entité) MORETTI LUIGI
  • Revue Lancet Reg Health Eur
  • Date de publication 2024-09
Coverage with evidence development program on stereotactic body radiotherapy in Belgium (2013-2019): a nationwide registry-based prospective study.
  • Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

  • Auteurs Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Yves-Pierga J, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M
  • Auteurs (entité) AFTIMOS PHILIPPE
  • Revue J Clin Oncol
  • Date de publication 2024-09
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
  • Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.

  • Auteurs Agostinetto E, Bruzzone M, Hamy AS, Kim HJ, Chiodi C, Bernstein-Molho R, Linn S, Pogoda K, Carrasco E, Derouane F, Bajpai J, Nader-Marta G, Lopetegui-Lia N, Partridge AH, Cortesi L, Rousset-Jablonski C, Giugliano F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Aguilar Y Mendez D, De Marchis L, Borea R, Puglisi F, Pistelli M, Kufel-Grabowska J, Di Rocco R, Mariamidze E, Atzori F, Kourie HR, Popovic L, de Azambuja E, Blondeaux E, Lambertini M
  • Auteurs (entité) AGOSTINETTO ELISA
  • Revue ESMO Open
  • Date de publication 2024-09
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.
Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasme

Huderf hospital

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet